Cardiovascular Disease Early Detection and Prevention Act of 2026
- Sponsor
- Rep. Cherfilus-McCormick, Sheila [D-FL-20]
- Committees
- Ways and Means Committee (primary)
- Last action
- Apr 14, 2026
Bottom line
The bill expands no-cost-sharing coverage for advanced cardiovascular risk assessment tests to at-risk individuals across all major health insurance programs, aiming to improve early detection and prevention of heart disease.
What it actually does
This bill mandates that group health plans, individual health insurance coverage, Medicare, and Medicaid programs provide coverage for lipoprotein(a) (Lp(a)) and apolipoprotein B (ApoB) level testing without cost sharing. This coverage is specifically for individuals with a family history of premature cardiovascular disease, a personal history of myocardial infarction, stroke, or elevated LDL cholesterol, a diagnosis of diabetes mellitus or obesity, or other recognized cardiovascular risk factors.
Proponents argue
Proponents argue that this bill addresses a critical gap in current cardiovascular disease detection by ensuring coverage for advanced lipid tests like Lp(a) and ApoB, which are superior predictors of cardiovascular risk than routine cholesterol panels. They contend that early detection and intervention can significantly reduce the incidence of heart attacks and strokes, ultimately saving lives and potentially lowering long-term healthcare costs associated with advanced disease management.
Opponents contend
Critics may raise concerns about the potential for increased healthcare expenditures due to the expanded coverage mandate across private and public insurance programs. They might argue that while the tests are valuable, mandating coverage without cost-sharing could lead to over-testing or strain healthcare budgets, especially if the long-term cost savings from prevention do not materialize as expected or if the 'other recognized cardiovascular risk factors' clause is interpreted too broadly.
The bill is relatively short and clearly structured, making it accessible for an informed reader to understand its core provisions within a reasonable timeframe.
Section 3(a)
Mandatory Coverage for Private Health Plans
This provision amends the Public Health Service Act to require group health plans and individual health insurance coverage to cover testing for lipoprotein(a) and apolipoprotein B levels. This coverage must be provided without cost sharing (e.g., deductibles, copayments) for individuals who have specific risk factors, such as a family history of premature cardiovascular disease, a personal history of heart attack or stroke, diabetes, obesity, or other recognized cardiovascular risk factors.
Supporters argue
Supporters argue that this provision ensures that individuals with private insurance, who are at higher risk for cardiovascular disease, can access crucial early detection tests without financial barriers. This aligns with public health goals of preventive care and can lead to earlier interventions, potentially reducing severe health outcomes.
Critics contend
Critics may contend that mandating coverage for these tests without cost sharing could increase the financial burden on private insurers, potentially leading to higher premiums for all policyholders. They might also question the cost-effectiveness of universal no-cost coverage for these specific tests across all risk factor categories.
Tradeoffs
The provision balances the public health benefit of early disease detection and prevention against the potential for increased healthcare costs for private insurance plans and their enrollees.
Section 3(b)
Mandatory Coverage for Medicare
This section amends the Social Security Act to include lipoprotein(a) and apolipoprotein B level testing as a covered preventive service under Medicare Part B. Similar to private plans, this coverage is for individuals with specific cardiovascular risk factors and explicitly states that no cost sharing (deductibles or coinsurance) will apply to these tests for eligible beneficiaries.
Section 3(c)
Mandatory Coverage for Medicaid
This section amends the Social Security Act to require state Medicaid programs to cover lipoprotein(a) and apolipoprotein B level testing for individuals with specified cardiovascular risk factors. It also explicitly prohibits cost sharing for these tests for eligible Medicaid beneficiaries and ensures that benchmark and benchmark-equivalent coverage plans offered through Medicaid must include this testing.
Section 3(d)
Effective Date of Amendments
This section specifies that the amendments to the Public Health Service Act (for private plans) will apply to plan years beginning on or after 180 days following the bill's enactment. For Medicare and Medicaid, the amendments will apply to items and services or medical assistance furnished on or after that same date. This provides a transition period for health plans and government programs to implement the new requirements.
The bill mandates coverage for Lp(a) and ApoB testing for individuals with a specific list of risk factors, concluding with the broad category of 'or other recognized cardiovascular risk factors.'
Section 3(a)(4), 3(b)(1)(B), 3(c)(1)(C)
Why it matters:This phrasing is common legislative practice to allow for flexibility and adaptation to evolving medical knowledge without requiring new legislation. However, it can also lead to ambiguity in implementation.
Case for: Supporters argue that including 'other recognized cardiovascular risk factors' provides necessary flexibility for healthcare providers and insurers to incorporate new scientific understanding and clinical guidelines for identifying at-risk individuals, ensuring the bill remains relevant as medical science advances.
Case against: Critics might argue that this broad language could lead to inconsistent application across different health plans and programs, or potentially open the door to coverage mandates for a wider range of tests or conditions than initially intended, leading to unforeseen cost increases.
Estimated impact: This clause could significantly expand the eligible population for no-cost testing beyond the explicitly listed conditions, impacting millions of additional individuals and potentially billions in healthcare spending over time, depending on how 'other recognized' is defined by regulatory bodies or clinical practice.
In amending Section 1833 of the Social Security Act regarding Medicare cost sharing, the bill text refers to 'section 1861(ww)(1)(B)' instead of 'section 1861(xx)(1)(B)', which is the section created by the bill for Lp(a) and ApoB coverage.
Section 3(b)(2)(A) and (B)
Why it matters:Such errors are typically unintentional legislative mistakes that can occur during complex bill drafting. If not corrected, it could lead to ambiguity or legal challenges regarding the application of no-cost sharing for these tests under Medicare.
Case for: The clear intent of the bill is to waive cost sharing for the newly covered Lp(a) and ApoB tests under Medicare. This typo is likely an oversight that would be corrected through technical amendments or interpreted in line with the bill's overall purpose.
Case against: If strictly interpreted, the erroneous cross-reference could be argued to mean that the cost-sharing waiver does not apply to the Lp(a) and ApoB tests as intended, creating a loophole or requiring beneficiaries to pay for tests that the bill aims to make free.
Estimated impact: If uncorrected and strictly interpreted, this typo could negate the no-cost-sharing provision for Medicare beneficiaries for these specific tests, potentially impacting millions of seniors and leading to significant out-of-pocket costs for them. If corrected or broadly interpreted, the impact would be as intended by the bill.